Results 101 to 110 of about 24,414 (214)

Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes

Diabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aims Despite intensive lipid‐lowering therapy, individuals with atherosclerotic cardiovascular disease (ASCVD) exhibit residual inflammatory risk, which drives recurrent cardiovascular events. This risk is amplified in type 2 diabetes mellitus (T2DM), where a pro‐inflammatory milieu accelerates atherogenesis. Monocyte‐derived macrophages (MDMs)
J. K. Ward, M. U. Shah, K. Lee, P. E. Squires, C. E. Hills   +4 more
wiley   +1 more source

Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.

Circulation, 2021

semanticscholar   +1 more source

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk

South African Family Practice, 2016
Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease.
Natalie Schellack, Gustav Schellack, E. Bronkhorst   +2 more
doaj   +1 more source

RNA‐Based Therapies for Inherited Metabolic Disorders

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Inherited metabolic disorders (IMDs) are a diverse and complex group of genetic conditions resulting from deficiencies in enzymes, transporters, or cofactors. These deficiencies lead to metabolic dysfunction and severe clinical consequences. Despite significant progress in understanding their molecular basis, treatment options remain limited ...
Reddy Sreekanth Vootukuri, Sonam Gurung, Roopkatha Ghosh, Philippa B. Mills, Julien Baruteau, Haiyan Zhou   +5 more
wiley   +1 more source

Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9

Атеросклероз, 2015
The review presents the current data of scientific literature about different phases of clinical trials of monoclonal antibodies against the proprotein convertase subtilisin/kexin type 9 (PCSK9). The results of completed clinical trials and the review of
K. S. Astrakova, Yu. I. Ragino, E. V. Shakhtshneider, M. I. Voevoda   +3 more
doaj  

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

Journal of Lipid Research, 2010
Proprotein convertase, subtilisin/kexin type 9 (PCSK9), a key regulator of plasma LDL-cholesterol (LDL-c) and cardiovascular risk, is produced in liver and secreted into plasma where it binds hepatic LDL receptors (LDLR), leading to their degradation ...
Jeffrey D. Browning, Jay D. Horton
doaj   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, EarlyView.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source

Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort

Obesity, Volume 34, Issue 3, Page 579-587, March 2026.
ABSTRACT Objective This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet‐Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS).
Jesús Argente, Andrea M. Haqq, Jan Luca Schorfheide, Nicolas Touchot, Caroline Huber, Urs Wiedemann, Jeremy Pomeroy, on behalf of the Phase 3 BBS Trial Investigators, Wendy Chung, Karine Clément, Hélène Dollfus, Elizabeth Forsythe, Robert M. Haws, Gabriel Á. Martos‐Moreno, Christine Poitou, Jack A. Yanovski   +15 more
wiley   +1 more source

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, Volume 183, Issue 5, Page 990-1008, March 2026.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study

PLoS ONE, 2019
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic enzyme that regulates circulating low-density lipoprotein (LDL) cholesterol levels by binding to LDL receptors (LDLR) and promoting their degradation. Although PCSK9 inhibitors
C. Picard, Alexandre Poirier, S. Bélanger, A. Labonté, D. Auld, J. Poirier   +5 more
semanticscholar   +1 more source